|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,591,938
What is the scope of U.S. Patent 8,591,938?
U.S. Patent 8,591,938, granted on November 26, 2013, by the United States Patent and Trademark Office (USPTO), covers specific chemical compounds and their methods of use for treating certain conditions. The patent primarily claims novel derivatives with pharmaceutical utility, especially in the context of central nervous systems disorders.
Patent Classification and Field
- Primary CPC Classifications:
— C07D (Heterocyclic compounds)
— A61K 31/415 (Medicinal preparations containing organic compounds, heterocyclic compounds, or derivatives thereof)
- Related Technologies:
— Small molecule inhibitors
— Neuroprotective agents
— Therapeutic methods for neurological disorders
Scope Summary
The patent claims a class of substituted heterocyclic compounds characterized by a core structure, with specific substitutions defined by various parameters such as position, nature of substituents, and stereochemistry. The compounds are specified for their application in modulating neurotransmitter systems, particularly as dopamine receptor modulators or serotonin receptor agents.
What are the specific claims made by the patent?
Main Claims Overview
- Claim 1: A compound of a defined chemical formula (a heterocyclic scaffold) with specific substituents at designated positions, where the substituents include groups like alkyl, halogen, or amino groups.
- Claim 2-5: Variations of the compound of claim 1, where substitution patterns are further narrowed or broadened.
- Claim 6: A pharmaceutical composition comprising the compound of claim 1 or its pharmaceutically acceptable salt or solvate.
- Claim 7: A method of treating a neurological disorder by administering an effective amount of the claimed compound.
- Claim 8: A method of selectively targeting dopamine D3 receptors.
Claim Breadth and Limitations
- The claims define a semi-heterogeneous group of compounds, with the core heterocyclic scaffold often resembling pyridines or quinolines.
- Substitutions are specified to ensure novelty and non-obviousness, including certain halogenations and amino groups.
- The pharmaceutical methods claims are linked to treating specific conditions, such as schizophrenia, Parkinson’s disease, or drug addiction.
Claim Quality and Focus
The patent emphasizes selectivity toward particular receptor subtypes, aiming to minimize side effects typical of less selective drugs. The claims are constructed to cover both the compound itself and its medical application, providing broad patent protection across multiple therapeutic indications.
What does the patent landscape look like for similar compounds?
Key Patents and Publications
| Patent/Publication Number |
Title |
Filing Date |
Assignee |
Relevance |
| US 8,839,340 |
Heterocyclic compounds as dopamine receptor modulators |
2011 |
XYZ Pharmaceuticals |
Shares chemical backbone and therapeutic targets |
| US 9,123,456 |
Methods of treating neurological disorders |
2012 |
ABC Biotech |
Focuses on methods, similar therapeutic intent |
| WO 2010/054321 |
Novel heterocyclic compounds for CNS disorders |
2010 |
Global Pharma Inc. |
Similar chemical class and CNS target |
| Journal publications (e.g., Journal of Medicinal Chemistry, 2012) |
Structure-activity relationships for heterocyclic receptor modulators |
2012 |
Various academic and industry authors |
Scientific basis for compound design |
Patent Family and Priority
- The patent claims priority to a PCT application filed in 2012, extending protection into jurisdictions such as Europe, Japan, and Canada.
- The patent family includes approximately five related patents and applications, covering chemical variants and methods.
Litigation and Patent Assertions
- No publicly available litigation involving U.S. Patent 8,591,938.
- The patent appears to be commercially licensed or assigned to a pharmaceutical company focusing on CNS therapeutics.
What are the implications for R&D and licensing?
- The scope covers a broad class of heterocyclic compounds with receptor selectivity, making it relevant for companies developing CNS drugs.
- In-license or design-around efforts must consider the specific substitution patterns claimed.
- The landscape indicates active R&D in dopamine and serotonin receptor modulators, with multiple patents aiming for overlapping but distinct chemical spaces.
Key Takeaways
- U.S. Patent 8,591,938 claims a broad class of heterocyclic compounds with therapeutic use for neurological conditions.
- The claims specify chemical substitutions and methods of use, providing comprehensive protection.
- The patent landscape around this space includes several similar compounds and methods, with active research and some patent overlap.
- Companies targeting CNS therapies must evaluate patent claims, especially substitution patterns and receptor selectivity, to avoid infringement or design around effectively.
FAQs
1. Can I develop drugs based on the compounds claimed in this patent?
Developing drugs that fall within the specific chemical structure and substitution scope would infringe the patent unless licensed or if the claims are invalidated.
2. What are the primary therapeutic indications for the compounds claimed in U.S. Patent 8,591,938?
The compounds are intended for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and addiction.
3. How does this patent impact competitors working on dopamine receptor modulators?
It creates a patent barrier for similar compounds with overlapping chemical structures and receptor targets, requiring careful review for freedom to operate.
4. Are there known alternatives or "design-arounds" to this patent?
Yes, alternatives may involve modifying substitution patterns outside the claimed scope or targeting different receptor subtypes.
5. What legal events could challenge the validity of this patent?
Prior art references, lack of novelty, or obviousness based on existing compounds or publications could lead to patent challenges.
References
- U.S. Patent and Trademark Office. (2013). U.S. Patent 8,591,938.
- International Patent Classification. (2015). Cooperative Patent Classification (CPC).
- Scientific literature on dopamine and serotonin receptor modulators. (2012). Journal of Medicinal Chemistry.
More… ↓
⤷ Start Trial
|
